- Conditions
- Lupus Nephritis
- Interventions
- Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 11
- States / cities
- Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,396
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Basal Cell Nevus Syndrome, Gorlin's Syndrome
- Interventions
- Vismodegib, Aminolevulinic acid %20 topical solution
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Oakland, California • New York, New York
- Conditions
- Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma, Follicular Lymphoma Grade 3B
- Interventions
- Mosunetuzumab, DHAX, ICE
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Growth Hormone Deficiency
- Interventions
- Not listed
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 18 Years to 25 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Lymphoma, Lymphoma, Large B-Cell, Diffuse
- Interventions
- Glofitamab, Polatuzumab, Rituximab, Doxorubicin Hydrochloride, Cyclophosphamide, Prednisone
- Drug
- Lead sponsor
- Jennifer Crombie, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 3
- States / cities
- Miami, Florida • Boston, Massachusetts
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
- Interventions
- Serum Neurofilament Light
- Diagnostic Test
- Lead sponsor
- Dent Neuroscience Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Amherst, New York
- Conditions
- Cystoid Macular Edema
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- Up to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Venetoclax, Gilteritinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 8 more
- Conditions
- Basal Cell Carcinoma
- Interventions
- Vismodegib 150 mg
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 17 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Everolimus, GDC-0980
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 5 more
- Conditions
- Breast Cancer
- Interventions
- Bevacizumab, Pictilisib, Letrozole, Paclitaxel, Trastuzumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Peoria, Illinois • Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
- Interventions
- Atezolizumab, Tocilizumab, Etrumadenant
- Drug
- Lead sponsor
- David Oh
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- San Francisco, California • St Louis, Missouri
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Stage 3 Cancer, Stage 4 Cancer
- Interventions
- Bevacizumab, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Zanubrutinib, Obinutuzumab, Sonrotoclax
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer, Carcinoma of the Breast
- Interventions
- Paclitaxel, Trastuzumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2022
- U.S. locations
- 20
- States / cities
- San Francisco, California • Maywood, Illinois • Indianapolis, Indiana + 13 more
- Conditions
- Ischemic Stroke
- Interventions
- IV tpa (Alteplase) vs IA tpa (Alteplase)
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments
- Other
- Lead sponsor
- Anza Memon
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- ABT-199, bortezomib, dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Jacksonville, Florida • Chicago, Illinois + 2 more
- Conditions
- Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
- Interventions
- Bexarotene (Targretin®), Erlotinib (Tarceva™)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Metastatic Breast Cancer, Breast Cancer, Progressive Breast Cancer
- Interventions
- carboplatin, bevacizumab, herceptin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers
- Interventions
- osimertinib, Bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Atezolizumab, PEGPH20
- Drug
- Lead sponsor
- Gulam Manji
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate
- Interventions
- Bevacizumab, Docetaxel
- Drug
- Lead sponsor
- Mary-Ellen Taplin, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Durham, North Carolina
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 34 more